ArticleTranslational cancer research2026

Matching-adjusted indirect comparison between asciminib and flumatinib as first-line treatment for chronic myeloid leukemia in China.

Ying Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.